Global eradication of measles: An epidemiologic and economic evaluation

Journal of Infectious Diseases

Volumn 204, Issue SUPPL. 1, 2011, Pages

  Levin, Ann ^a   Burgess, Colleen ^b   Garrison Jr , Louis P ^c   Bauch, Chris ^d   Babigumira, Joseph ^c   Simons, Emily ^e   Dabbagh, Alya ^e  

^a Independent Department   (United States)

^b MathEcology   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF GUELPH   (Canada)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE;

ARTICLE; BANGLADESH; BRAZIL; COLOMBIA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ETHIOPIA; HEALTH CARE FINANCING; HUMAN; MEASLES; MEASLES VACCINATION; MORTALITY; PRIORITY JOURNAL; RISK REDUCTION; TAJIKISTAN; UGANDA; BIOLOGICAL MODEL; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH; STATISTICAL MODEL; VACCINATION;

COST-BENEFIT ANALYSIS; HUMANS; MEASLES; MEASLES VACCINE; MODELS, BIOLOGICAL; MODELS, ECONOMIC; VACCINATION; WORLD HEALTH;

EID: 79960865424     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir096     Document Type: Article

References (16)

1. World Health Organization. GIVS: global immunization vision and strategy 2006-2015. Geneva: World Health Organization and UNICEF, 2005. http://www.who.int/vaccines-documents/docspdf05/givs-final-en.pdf. Accessed 24 August 2010.
2. Centers for Disease Control and Prevention. Global measles mortality, 2000-2008. MMWR Morb Mortal Wkly Rep 2009; 58:1321-6.
3. SIXTY-THIRD World Health Assembly May 2010, A63/18, Geneva, Switzerland: World Health Organization.
4. Dabbagh, Alya. Presentation on "Assessing the feasibility of global measles elimination" at Meeting of the Sage Working Group on Measles, January 29-30, Geneva, Switzerland: World Health Organization.
5. Griffin DE, Moss WJ. Can we eradicate measles? Microbe 2006; 1:409-13.
6. Cutts FT. The immunological basis for immunization: Measles. WHO/EPI/GEN/93.17, 1993. Unpublished document.
7. Weekly epidemiological record. Measles Vaccine. WHO position paper. Wkly Epidemiol Rec 2009; 35:349-60.
8. World Health Organization. WHO Guide for standardization of economic evaluations of immunization programmes. http://www.who.int/werWHO. Accessed 24 August 2010.
9. Gold M, Siegel J, Russell L, Weinstein M. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
10. Bauch CT, Earn DJD. Transients and Attractors in Epidemics. Proc Biol Sci 2003; 270:1573-8.
11. Mossong J, Hens N, Jit M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008; 5:0381-91.
12. AAP. Measles. Pickering L ed: Red Book: 2006 Report of the Committee on Infectious Diseases, 27th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2006; 441-52.
13. Collier L, Oxford J. Human Virology, 3rd ed. New York: Oxford University Press, 2006.
14. Otten M, Okwo-Bele J, Kezaala R, Biellik R, Eggers R, Nshimirimana D. Impact of alternative approaches to accelerated measles control: experience in the African region, 1996-2002. J Infect Dis 2003; 187(Suppl. 1);S36-43.
15. Hull H, Williams P, Oldfield F. Measles mortality and vaccine efficacy in rural West Africa. Lancet 1983; 1:972-5.
16. Samb B, Aaby P, Whittle H, Seck A, Simondon F. Protective efficacy of hightitremeasles vaccines administered fromthe age of five months: a community study in rural Senegal. Trans R Soc Trop Med Hyg 1993; 87:697-701.